YU2602A - Polimorfna so - Google Patents

Polimorfna so

Info

Publication number
YU2602A
YU2602A YU2602A YUP2602A YU2602A YU 2602 A YU2602 A YU 2602A YU 2602 A YU2602 A YU 2602A YU P2602 A YUP2602 A YU P2602A YU 2602 A YU2602 A YU 2602A
Authority
YU
Yugoslavia
Prior art keywords
polymorphic salt
polymorphic
migraine
agonist
receptors
Prior art date
Application number
YU2602A
Other languages
English (en)
Inventor
Arthur Bentley
Simon Howard-Field
Ronald James Ogilvie
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU2602A publication Critical patent/YU2602A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ovaj pronalazak se odnosi na kristalni, polimorfni oblik jedinjenja formule (I) okarakterisan rengenskim difrakcionim dijagramom praha koji je dobijen korišćenjem bakar K-alfa, zračenja (λ=0.15046nm) sa glavnim pikovima na 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 i 25.79. Pronalazak se takodje odnosi na postupke za dobijanje navedenog oblika, na farmaceutske preparate koji sadrže ovaj polimorf.[The present invention is concerned with a crystalline, polymorphic form of a compound of formula (I) characterised by a powder X- ray diffraction pattern obtained using copper K-alpha1 radiation (γ = 0.15046 nm) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 and 25.79. The invention also relates to processes for the preparation of said form, to pharmaceutical compositions containing same and to its use in medicine, particularly the treatment of conditions for which an agonist of 5-HT1 receptors is indicated, for example, migraine.
YU2602A 1999-09-28 2000-09-14 Polimorfna so YU2602A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt

Publications (1)

Publication Number Publication Date
YU2602A true YU2602A (sh) 2004-11-25

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2602A YU2602A (sh) 1999-09-28 2000-09-14 Polimorfna so

Country Status (50)

Country Link
US (1) US6369094B1 (sh)
EP (1) EP1233960B1 (sh)
JP (1) JP3795395B2 (sh)
KR (1) KR100479897B1 (sh)
CN (1) CN1155594C (sh)
AP (1) AP2004A (sh)
AR (1) AR025779A1 (sh)
AT (1) ATE246185T1 (sh)
AU (1) AU779580B2 (sh)
BG (1) BG65161B1 (sh)
BR (1) BR0014272A (sh)
CA (1) CA2379572C (sh)
CO (1) CO5180567A1 (sh)
CR (1) CR6561A (sh)
CU (1) CU23200A3 (sh)
CZ (1) CZ2002971A3 (sh)
DE (1) DE60004262T2 (sh)
DK (1) DK1233960T3 (sh)
DZ (1) DZ3254A1 (sh)
EA (1) EA004510B1 (sh)
EE (1) EE200200171A (sh)
EG (1) EG24143A (sh)
ES (1) ES2200911T3 (sh)
GB (1) GB9922963D0 (sh)
GE (1) GEP20043365B (sh)
GT (1) GT200000159A (sh)
HK (1) HK1048628B (sh)
HR (1) HRP20020270B1 (sh)
HU (1) HUP0202821A3 (sh)
IL (1) IL147154A (sh)
IS (1) IS2162B (sh)
MA (1) MA26821A1 (sh)
MX (1) MXPA02003311A (sh)
MY (1) MY121170A (sh)
NO (1) NO321936B1 (sh)
NZ (1) NZ516093A (sh)
OA (1) OA12024A (sh)
PA (1) PA8498901A1 (sh)
PE (1) PE20010662A1 (sh)
PL (1) PL354960A1 (sh)
PT (1) PT1233960E (sh)
SI (1) SI1233960T1 (sh)
SK (1) SK3982002A3 (sh)
TN (1) TNSN00187A1 (sh)
TR (1) TR200200804T2 (sh)
TW (1) TWI265926B (sh)
UA (1) UA72272C2 (sh)
WO (1) WO2001023377A2 (sh)
YU (1) YU2602A (sh)
ZA (1) ZA200202406B (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
EP1819323B2 (en) * 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ， インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
RU2095360C1 (ru) * 1990-10-15 1997-11-10 Пфайзер Инк. Производные индола, их оптические изомеры и фармацевтически приемлемые соли
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
PL337803A1 (en) * 1997-07-03 2000-09-11 Pfizer Pharmaceutic agents containing eletriptane hemisulphate and caffeine

Also Published As

Publication number Publication date
KR20020032627A (ko) 2002-05-03
DK1233960T3 (da) 2003-10-27
IS2162B (is) 2006-11-15
EA004510B1 (ru) 2004-04-29
BG65161B1 (bg) 2007-04-30
CR6561A (es) 2005-04-04
DZ3254A1 (fr) 2001-04-05
NO321936B1 (no) 2006-07-24
EE200200171A (et) 2003-06-16
NO20021525L (no) 2002-03-26
DE60004262D1 (de) 2003-09-04
CZ2002971A3 (cs) 2003-04-16
HK1048628B (zh) 2004-10-21
EG24143A (en) 2008-08-06
SK3982002A3 (en) 2003-05-02
HRP20020270B1 (en) 2004-04-30
BG106240A (en) 2002-07-31
AP2002002457A0 (en) 2002-06-30
EP1233960A2 (en) 2002-08-28
HRP20020270A2 (en) 2003-06-30
MY121170A (en) 2005-12-30
GEP20043365B (en) 2004-05-10
CO5180567A1 (es) 2002-07-30
HK1048628A1 (en) 2003-04-11
ATE246185T1 (de) 2003-08-15
CN1155594C (zh) 2004-06-30
HUP0202821A3 (en) 2003-12-29
MA26821A1 (fr) 2004-12-20
SI1233960T1 (en) 2003-12-31
IL147154A0 (en) 2002-08-14
IL147154A (en) 2005-11-20
AU6721300A (en) 2001-04-30
CA2379572A1 (en) 2001-04-05
MXPA02003311A (es) 2002-10-04
IS6223A (is) 2002-01-08
OA12024A (en) 2006-04-19
US6369094B1 (en) 2002-04-09
NZ516093A (en) 2005-01-28
JP2003510318A (ja) 2003-03-18
ZA200202406B (en) 2003-05-28
ES2200911T3 (es) 2004-03-16
PE20010662A1 (es) 2001-06-23
GB9922963D0 (en) 1999-12-01
JP3795395B2 (ja) 2006-07-12
PA8498901A1 (es) 2004-02-07
AU779580B2 (en) 2005-01-27
BR0014272A (pt) 2002-05-21
TNSN00187A1 (fr) 2005-11-10
HUP0202821A2 (hu) 2003-01-28
CN1364166A (zh) 2002-08-14
WO2001023377A2 (en) 2001-04-05
DE60004262T2 (de) 2004-01-22
CA2379572C (en) 2006-11-14
WO2001023377A3 (en) 2002-03-07
CU23200A3 (es) 2007-04-06
EA200200302A1 (ru) 2002-10-31
WO2001023377A9 (en) 2002-03-28
GT200000159A (es) 2002-03-20
KR100479897B1 (ko) 2005-03-31
TWI265926B (en) 2006-11-11
TR200200804T2 (tr) 2002-07-22
UA72272C2 (uk) 2005-02-15
AR025779A1 (es) 2002-12-11
EP1233960B1 (en) 2003-07-30
PT1233960E (pt) 2003-11-28
PL354960A1 (en) 2004-03-22
NO20021525D0 (no) 2002-03-26
AP2004A (en) 2009-06-10

Similar Documents

Publication Publication Date Title
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
YU2602A (sh) Polimorfna so
GEP20043361B (en)  Crystalline Form of Perindopril Tert-Butylamine Salt,
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
AP1407A (en) Novel ß Crystalline Form of Perindopril Tert-Butylamine Salt, Preparation Method, And Pharmaceutical Compositions Containing Same.
CA2415447A1 (fr) Nouvelle forme cristalline .gamma. du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
MA28451B1 (fr) Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
NZ244016A (en) Crystalline form of (r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl) indol-3-ylmethyl]-n-(2-methylphenylsulphonyl)benzamide
TW200509906A (en) Crystalline 1-methylcarbapenem compounds
ECSP003681A (es) Sal polimorfica
TH80938A (th) เกลือที่มีหลายรูปแบบ